A Phase 3 interventional study of NNC0487-0111 and Placebo (matched to NNC0487-0111) in Diabetes Mellitus, Overweight and Obesity, sponsored by Novo Nordisk A/S. Active, not recruiting at 73 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 642 studies in Diabetes Mellitus by Novo Nordisk A/S — 2 open to participants now, 3 under way, 1 of them phase 3. Diabetes Mellitus · Novo Nordisk A/S.
Among the 642 studies in Diabetes Mellitus by Novo Nordisk A/S, this one is the 48th largest by planned enrollment of the 494 interventional ones that give a count, is one of 2 that started in 2026, is one of 182 in phase 3, and was the 641st registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,074 are open to participants now.
Browse Diabetes Mellitus studies →2 of the 642 studies in Diabetes Mellitus by Novo Nordisk A/S are open now, in 2 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Germany
Ages 18–75
Novo Nordisk A/S · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 650 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 197 (30%) stop at 75 or younger; 88 take children under 18; 183 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
642 studies; the count open now beside each. This study's row is marked.
First in 1989; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 638 is above the median of 80 across 6,024 interventional studies indexed under Diabetes Mellitus.
Median enrollment 87 across the 494 interventional studies, 1,497 across the 148 observational. Of the 636 that completed or were terminated, 163 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
1 of the studies in Diabetes Mellitus by Novo Nordisk A/S that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07535307Novo Nordisk A/SInvestigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 Diabetes | 2027-11-11 |
Add it to your calendar (.ics) → With an account.
Among the 642 studies in Diabetes Mellitus by Novo Nordisk A/S, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomized to receive NNC0487-0111 dose level 1 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
Drug: NNC0487-0111
Participants will be randomized to receive NNC0487-0111 dose level 2 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
Drug: NNC0487-0111
Participants will be randomized to receive NNC0487-0111 dose level 3 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
Drug: NNC0487-0111
Participants will be randomized to receive NNC0487-0111 dose level 4 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
Drug: NNC0487-0111
Participants will receive placebo matched to NNC0487-0111 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
Drug: Placebo (matched to NNC0487-0111)
NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.
Placebo matched to NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.
Relative change in body weight
Measured as percentage (%) of body weight.
Time frame: From baseline (week 0) to (week 84)
Change in waist circumference
Measured as centimetre (cm).
Time frame: From baseline (week 0) to (week 84)
Change in glycated haemoglobin (HbA1c)
Measured as percentage (%) of HbA1c.
Time frame: From baseline (week 0) to (week 84)
Change in systolic blood pressure (SBP)
Measured as millimetre of mercury (mmHg).
Time frame: From baseline (week 0) to (week 84)
Change in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) physical function score
Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. The physical function score ranges from 0-100. Higher scores indicate better levels of functioning.
Time frame: From baseline (week 0) to (week 84)
Change in SF-36v2® Health Survey Acute (SF-36v2 Acute) physical functioning score
Measured as score on a scale. SF-36v2 Acute measures Health-Related Quality of Life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation (SD) of 10. The physical functioning ranges from 19.0 to 57.6. Higher scores indicate better functional health and well-being.
Time frame: From baseline (week 0) to (week 84)
Change in body weight
Measured as kilogram (kg).
Time frame: From baseline (week 0) to (week 84)
Change in body mass index (BMI)
Measured as kilograms per meter squared (kg/m\^2).
Time frame: From baseline (week 0) to (week 84)
Change in IWQOL-Lite-CT: Physical, Psychosocial, Total score
Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. The physical function score ranges from 0-100. Higher scores indicate better levels of functioning.
Time frame: From baseline (week 0) to (week 84)
Achievement of HbA1c < 7.0% (Yes/No)
Measured as number of participants
Time frame: From baseline (week 0) to (week 84)
Achievement of HbA1c ≤ 6.5% (Yes/No)
Measured as number of participants
Time frame: From baseline (week 0) to (week 84)
Achievement of HbA1c < 5.7% (Yes/No)
Measured as number of participants
Time frame: From baseline (week 0) to (week 84)
Change in fasting plasma glucose (FPG) (mmol/L)
Measured as millimoles per liter (mmol/L)
Time frame: From baseline (week 0) to (week 84)
Change in fasting plasma glucose (FPG) (mg/dL)
Measured as milligram per deciliter (mg/dL)
Time frame: From baseline (week 0) to (week 84)
Change in fasting insulin
Measured as ratio to baseline.
Time frame: From baseline (week 0) to (week 84)
Change in urinary albumin-to-creatinine ratio (UACR)
Measured as ratio to baseline.
Time frame: From baseline (week 0) to (week 84)
Change in diastolic blood pressure
Measured as mmHg.
Time frame: From baseline (week 0) to (week 84)
Change in high-sensitivity C-reactive protein (hsCRP)
Measured as ratio to baseline.
Time frame: From baseline (week 0) to (week 84)
Number of Treatment Emergent Adverse Events (TEAEs)
Measured as count of events.
Time frame: From baseline (week 0) to week 88
Number of Treatment Emergent Serious Adverse Events (TESAEs)
Measured as count of events.
Time frame: From baseline (week 0) to week 88
Number of Treatment Emergent Adverse Events (TEAEs) leading to permanent treatment discontinuation
Measured as count of events.
Time frame: From baseline (week 0) to week 88
Number of treatment emergent clinically significant hypoglycaemic episodes (level 2) (< 3.0 mmol/L (54 mg/dL), confirmed by a blood glucose (BG) meter)
Measured as number of episodes
Time frame: From baseline (week 0) to week 88
Number of treatment emergent severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold
Measured as number of episodes
Time frame: From baseline (week 0) to week 88
Change in Total cholesterol
Measured as ratio to baseline.
Time frame: From baseline (week 0) to (week 84)
Change in High-density lipoprotein (HDL) cholesterol
Measured as ratio to baseline.
Time frame: From baseline (week 0) to (week 84)
Change in Low-density lipoprotein (LDL) cholesterol
Measured as ratio to baseline.
Time frame: From baseline (week 0) to (week 84)
Change in Very low-density lipoprotein (VLDL) cholesterol
Measured as ratio to baseline.
Time frame: From baseline (week 0) to (week 84)
Change in Non-HDL cholesterol
Measured as ratio to baseline.
Time frame: From baseline (week 0) to (week 84)
Change in Triglycerides
Measured as ratio to baseline.
Time frame: From baseline (week 0) to (week 84)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Aug 2028, 27 months after the start.
Of 167 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's planned 27 months is above that.
Counting every sponsor, half of 230 studies reached it within 19 months; a quarter within 13 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zenagamtide